Welcome to our dedicated page for GENMAB A/S SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GENMAB A/S's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GENMAB A/S's regulatory disclosures and financial reporting.
Genmab A/S has filed a Form 6-K to furnish a company announcement stating that it plans to acquire Merus. The announcement highlights that the deal is intended to expand Genmab’s late-stage drug pipeline and accelerate a shift toward a wholly owned product model, meaning Genmab aims to control more of its future medicines rather than relying mainly on partnerships.
The Form 6-K is also designated to be incorporated by reference into several existing Genmab registration statements on Form S-8, so the information in this report becomes part of those employee share incentive-related filings.
Genmab A/S filed a Form 6-K as a foreign private issuer for September 2025. The filing notes that a company announcement dated September 26, 2025 covers the grant of restricted stock units and warrants to employees of Genmab.
The Form 6-K is deemed incorporated by reference into several existing Genmab registration statements on Form S-8, meaning the information in this report becomes part of those employee equity compensation-related registrations from the filing date, unless later superseded by other filings.
Genmab A/S has furnished a Form 6-K for September 2025 that attaches two exhibits related to a major shareholder. The exhibits are a company announcement dated September 23, 2025 and a standard notification of major holdings. The filing is incorporated by reference into Genmab’s existing Form S-8 registration statements.
Genmab A/S submitted a Form 6-K for September 2025 that attaches two company announcements dated September 9, 2025. One announcement describes a capital increase in Genmab resulting from employee warrant exercises. The other details transactions in Genmab shares and linked securities by managerial employees and their closely associated persons.
The Form 6-K is also deemed incorporated by reference into several existing Genmab registration statements on Form S-8, making these announcements part of those share-based compensation plans’ disclosure record.
Genmab A/S filed a Form 6-K as a foreign private issuer for August 2025. The report primarily forwards an attached company announcement describing a capital increase in Genmab resulting from the exercise of employee warrants. The filing also specifies that this 6-K is incorporated by reference into several existing Genmab Form S-8 registration statements covering employee equity compensation plans.
Genmab’s H1-25 6-K shows solid growth and an upgraded FY-25 outlook. Revenue climbed 19 % YoY to $1.64 bn on stronger DARZALEX (+22 % J&J sales), Kesimpta and EPKINLY. Royalty income rose 24 % to $1.38 bn, representing 84 % of total revenue. Operating profit increased 56 % to $548 m as costs grew only 6 %, expanding the margin to 33 %. Net profit reached $531 m.
Liquidity remains robust with $1.30 bn cash and $1.60 bn marketable securities; equity ratio is 82 %. Functional and presentation currency switched to USD on 1 Jan 25.
Revised 2025 guidance: revenue $3.5-3.7 bn (mid-point +$100 m), operating profit $1.055-1.405 bn (mid-point +$100 m); operating-expense range unchanged.
Operational highlights: sBLA filed for epcoritamab+R2 in r/r FL; Tivdak launched in Japan; Rina-S posted 50 % ORR in endometrial cancer; >40 epcoritamab abstracts presented. Workforce up to 2,639 FTEs.
Risks & negatives: TEPEZZA royalties -8 %; lower reimbursement revenue; ongoing Chugai patent suit and AbbVie trade-secret litigation; FX gains moderated after USD switch.